Cargando…
Should We Use Standard Survival Models or the Illness-Death Model for Interval-Censored Data to Investigate Risk Factors of Chronic Kidney Disease Progression?
BACKGROUND: In studies investigating risk factors of chronic kidney disease (CKD) progression, one may be interested in estimating factors effects on both a fall of glomerular filtration rate (GFR) below a specific level (i.e., a CKD stage) and death. Such studies have to account for the fact that G...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263704/ https://www.ncbi.nlm.nih.gov/pubmed/25503256 http://dx.doi.org/10.1371/journal.pone.0114839 |
_version_ | 1782348615562297344 |
---|---|
author | Boucquemont, Julie Metzger, Marie Combe, Christian Stengel, Bénédicte Leffondre, Karen |
author_facet | Boucquemont, Julie Metzger, Marie Combe, Christian Stengel, Bénédicte Leffondre, Karen |
author_sort | Boucquemont, Julie |
collection | PubMed |
description | BACKGROUND: In studies investigating risk factors of chronic kidney disease (CKD) progression, one may be interested in estimating factors effects on both a fall of glomerular filtration rate (GFR) below a specific level (i.e., a CKD stage) and death. Such studies have to account for the fact that GFR is measured at intermittent visit only, which implies that progression to the stage of interest is unknown for patients who die before being observed at that stage. Our objective was to compare the results of an illness-death model that handles this uncertainty, with frequently used survival models. METHODS: This study included 1,519 patients from the NephroTest cohort with CKD stages 1–4 at baseline (69% males, 59±15 years, median protein/creatinine ratio [PCR] 27.4 mg/mmol) and subsequent annual measures of GFR (follow-up time 4.3±2.7 years). Each model was used to estimate the effects of sex, age, PCR, and GFR at baseline on the hazards of progression to CKD stage 5 (GFR<15 mL/min/1.73 m(2), n = 282 observed) and death (n = 168). RESULTS: For progression to stage 5, there were only minor differences between results from the different models. The differences between results were higher for the hazard of death before or after progression. Our results also suggest that previous findings on the effect of age on end-stage renal disease are more likely due to a strong impact of age on death than to an effect on progression. The probabilities of progression were systematically under-estimated with the survival model as compared with the illness-death model. CONCLUSIONS: This study illustrates the advantages of the illness-death model for accurately estimating the effects of risk factors on the hazard of progression and death, and probabilities of progression. It avoids the need to choose arbitrary time-to-event and time-to-censoring, while accounting for both interval censoring and competition by death, using a single analytical model. |
format | Online Article Text |
id | pubmed-4263704 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-42637042014-12-19 Should We Use Standard Survival Models or the Illness-Death Model for Interval-Censored Data to Investigate Risk Factors of Chronic Kidney Disease Progression? Boucquemont, Julie Metzger, Marie Combe, Christian Stengel, Bénédicte Leffondre, Karen PLoS One Research Article BACKGROUND: In studies investigating risk factors of chronic kidney disease (CKD) progression, one may be interested in estimating factors effects on both a fall of glomerular filtration rate (GFR) below a specific level (i.e., a CKD stage) and death. Such studies have to account for the fact that GFR is measured at intermittent visit only, which implies that progression to the stage of interest is unknown for patients who die before being observed at that stage. Our objective was to compare the results of an illness-death model that handles this uncertainty, with frequently used survival models. METHODS: This study included 1,519 patients from the NephroTest cohort with CKD stages 1–4 at baseline (69% males, 59±15 years, median protein/creatinine ratio [PCR] 27.4 mg/mmol) and subsequent annual measures of GFR (follow-up time 4.3±2.7 years). Each model was used to estimate the effects of sex, age, PCR, and GFR at baseline on the hazards of progression to CKD stage 5 (GFR<15 mL/min/1.73 m(2), n = 282 observed) and death (n = 168). RESULTS: For progression to stage 5, there were only minor differences between results from the different models. The differences between results were higher for the hazard of death before or after progression. Our results also suggest that previous findings on the effect of age on end-stage renal disease are more likely due to a strong impact of age on death than to an effect on progression. The probabilities of progression were systematically under-estimated with the survival model as compared with the illness-death model. CONCLUSIONS: This study illustrates the advantages of the illness-death model for accurately estimating the effects of risk factors on the hazard of progression and death, and probabilities of progression. It avoids the need to choose arbitrary time-to-event and time-to-censoring, while accounting for both interval censoring and competition by death, using a single analytical model. Public Library of Science 2014-12-11 /pmc/articles/PMC4263704/ /pubmed/25503256 http://dx.doi.org/10.1371/journal.pone.0114839 Text en © 2014 Boucquemont et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Boucquemont, Julie Metzger, Marie Combe, Christian Stengel, Bénédicte Leffondre, Karen Should We Use Standard Survival Models or the Illness-Death Model for Interval-Censored Data to Investigate Risk Factors of Chronic Kidney Disease Progression? |
title | Should We Use Standard Survival Models or the Illness-Death Model for Interval-Censored Data to Investigate Risk Factors of Chronic Kidney Disease Progression? |
title_full | Should We Use Standard Survival Models or the Illness-Death Model for Interval-Censored Data to Investigate Risk Factors of Chronic Kidney Disease Progression? |
title_fullStr | Should We Use Standard Survival Models or the Illness-Death Model for Interval-Censored Data to Investigate Risk Factors of Chronic Kidney Disease Progression? |
title_full_unstemmed | Should We Use Standard Survival Models or the Illness-Death Model for Interval-Censored Data to Investigate Risk Factors of Chronic Kidney Disease Progression? |
title_short | Should We Use Standard Survival Models or the Illness-Death Model for Interval-Censored Data to Investigate Risk Factors of Chronic Kidney Disease Progression? |
title_sort | should we use standard survival models or the illness-death model for interval-censored data to investigate risk factors of chronic kidney disease progression? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263704/ https://www.ncbi.nlm.nih.gov/pubmed/25503256 http://dx.doi.org/10.1371/journal.pone.0114839 |
work_keys_str_mv | AT boucquemontjulie shouldweusestandardsurvivalmodelsortheillnessdeathmodelforintervalcensoreddatatoinvestigateriskfactorsofchronickidneydiseaseprogression AT metzgermarie shouldweusestandardsurvivalmodelsortheillnessdeathmodelforintervalcensoreddatatoinvestigateriskfactorsofchronickidneydiseaseprogression AT combechristian shouldweusestandardsurvivalmodelsortheillnessdeathmodelforintervalcensoreddatatoinvestigateriskfactorsofchronickidneydiseaseprogression AT stengelbenedicte shouldweusestandardsurvivalmodelsortheillnessdeathmodelforintervalcensoreddatatoinvestigateriskfactorsofchronickidneydiseaseprogression AT leffondrekaren shouldweusestandardsurvivalmodelsortheillnessdeathmodelforintervalcensoreddatatoinvestigateriskfactorsofchronickidneydiseaseprogression AT shouldweusestandardsurvivalmodelsortheillnessdeathmodelforintervalcensoreddatatoinvestigateriskfactorsofchronickidneydiseaseprogression |